APA (7th ed.) Citation

R, O., S, O., T, M., R, W., S, Y., M, K., . . . G, K. (2025). Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate. Pharmaceutics, 17(12), . https://doi.org/10.3390/pharmaceutics17121627

Chicago Style (17th ed.) Citation

R, Ohashi, Otake S, Murata T, Watari R, Yoshida S, Kitade M, Kondo D, and Kimura G. "Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate." Pharmaceutics 17, no. 12 (2025). https://doi.org/10.3390/pharmaceutics17121627.

MLA (9th ed.) Citation

R, Ohashi, et al. "Selection of Solubility Enhancement Technologies for S-892216, a Novel COVID-19 Drug Candidate." Pharmaceutics, vol. 17, no. 12, 2025, https://doi.org/10.3390/pharmaceutics17121627.